The Asian Scientist 100
Long Ran
Institution
University of Science and Technology of China
Country
China
Field
Chemistry
Long won the 2017 L’Oréal UNESCO For Women in Science International Rising Talent award for her research on photocatalysts for carbon dioxide reduction.
(Photo: L’oréal Foundation)
AWARDS
- 2017 LOréal-UNESCO For Women in Science International Rising Talent Award
Related articles
Inviragen Advances Dengue Vaccine Into Second Stage Of Phase II Study
Inviragen, Inc. has initiated the second stage of an ongoing Phase II study of DENVax™, its investigational dengue vaccine.
Pakistan Braces For Rise In Dengue Cases During Monsoon Season
Pakistani health officials are bracing for a surge in dengue fever cases as the country enjoys its first monsoon showers this week.
Global Burden Of Dengue Is Triple Current Estimates, Study Says
The global burden of dengue infection is more than triple current estimates from the World Health Organization (WHO), a new study says.
Record Dengue Season Predicted In Thailand
With more than 40 deaths and almost 40,000 cases of dengue fever reported in Thailand so far this year, health experts are warning this could be the largest-ever epidemic.
New Insights From Tracking Dengue Incidence In Thailand
Researchers tracking the incidence of dengue fever in Thailand over a period of almost 40 years have uncovered new insights about the disease.
Artificial MicroRNAs To Target Dengue Virus
Researchers in China have identified artificial microRNAs that target regions of the dengue genome essential for viral replication.
Setback For Dengue-Blocking Mosquito Trial In Vietnam
A project to introduce mosquitoes that could potentially block dengue virus on an island off Vietnam has run into an early hurdle.
Japan Experiences First Dengue Outbreak In 70 Years
Japan's first dengue outbreak in 70 years underscores the rising impact of mosquito-borne diseases as global temperatures rise.
Visterra & A*STAR To Bring Dengue Antibody To Clinical Trials
A*STAR's D3 has joined Visterra to bring the dengue monoclonal antibody VIS513 to proof-of-concept clinical trials.